a Manufacturing , Commonwealth Scientific Industrial Research Organisation , Clayton , Australia.
b The Australian Regenerative Medicine Institute, Monash University , Clayton , Australia.
Platelets. 2017 Nov;28(7):649-656. doi: 10.1080/09537104.2016.1257783. Epub 2017 Jan 9.
Blood transfusion services face an ever-increasing demand for donor platelets to meet clinical needs. Whilst strategies for increasing platelet storage life and improving the efficiency of donor platelet collection are important, in the longer term, platelets generated by bio-manufacturing processes will be required to meet demands. Production of sufficient numbers of in vitro-derived platelets for transfusion represents a significant bioengineering challenge. In this review, we highlight recent progress in this area of research and outline the main technical and biological obstacles that need to be met before this becomes feasible and economic. A critical consideration is assurance of the functional properties of these cells as compared to their fresh, donor collected, counterparts. We contend that platelet-like particles and in vitro-derived platelets that phenotypically resemble fresh platelets must deliver the same functions as these cells upon transfusion. We also note recent progress with immortalized megakaryocyte progenitor cell lines, molecular strategies for reducing expression of HLA Class I to generate universal donor platelets and the move to early clinical studies with in vitro-derived platelets.
输血服务面临着越来越大的需求，需要供体血小板来满足临床需求。虽然增加血小板储存寿命和提高供体血小板采集效率的策略很重要，但从长远来看，生物制造过程产生的血小板将是满足需求的必要条件。生产足够数量的用于输血的体外衍生血小板是一个重大的生物工程挑战。在这篇综述中，我们强调了该研究领域的最新进展，并概述了在这变得可行和经济之前需要克服的主要技术和生物学障碍。一个关键的考虑因素是保证这些细胞的功能特性与它们的新鲜供体采集的对应物相比。我们认为，与新鲜血小板表型相似的血小板样颗粒和体外衍生的血小板在输注后必须发挥与这些细胞相同的功能。我们还注意到，最近在永生化巨核细胞祖细胞系、降低 HLA Ⅰ类表达以产生通用供体血小板的分子策略以及向体外衍生血小板的早期临床研究方面取得了进展。
